265783 Prevalence of Malaria in Pregnancy as Rwanda Moves towards Malaria Elimination

Tuesday, October 30, 2012 : 3:00 PM - 3:15 PM

Corine Karema , Ministry of Health of Rwanda, Kigali, Rwanda
William R. Brieger, MPH, CHES, DrPH , International Health, Bloomberg School of Public Health, The John Hopkins University, Baltimore, MD
Malaria has seen a steady decline in Rwanda, yet certain vulnerable groups such as pregnant women experience life-threatening episodes of malaria. In order to move closer to malaria elimination, Rwanda needed an accurate estimate of prevalence of malaria in pregnancy. A sample of 4050 newly pregnant women was chosen in six districts and 38 antenatal care (ANC) clinics across the country to determine the current level of malaria in pregnancy using rapid diagnostic tests administered by the health staff in charge of ANC clinics. Two districts each were chosen in areas of higher, moderate and lower malaria transmission. Overall 3% of pregnant women tested positive for malaria. This ranged from 6% in the relative higher prevalence districts to 1% in the expected moderate prevalence districts to 0% in the low prevalence districts. The results provide the National Malaria Control Program with evidence that malaria in Rwanda is currently a focal disease and that focused intervention, such as screening and treating pregnant women in focal transmission areas should ensure that continued progress is made toward eliminating malaria from the country and protecting the lives of pregnant women

Learning Areas:
Program planning

Learning Objectives:
1. Explain how malaria in pregnancy (MIP) prevalence can be determined at antenatal clinic 2. State levels in Rwanda 2. Suggest control measure to protecyt pregnant women from malaria

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am co-PI of project
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.